Novartis
4Q Revenues: $11.4 billion (+8%)
4Q Earnings: $2.6 billion (+101%)
FY Revenues: $45.4 billion (+8%)
FY Earnings: $8.6 billion (+42%)
Comments: Sales growth in the quarter was mainly driven by continued strong performance from Entresto (+27% to $1.6 billion), Kesimpta (+74% to $641 million), Kisqali (+71% cc to $610 million), Pluvicto (+53% to $273 million) and Scemblix (+143% cc to $125 million). Cosentyx sales were $1.3 billion in the quarter, up 21%. Promacta/Revolade sales were %563 million, up 4%. Tafinlar + Mekinist sales were $486 million, up 5%. Tasigna sales were down 6% to $446 million. Jakavi sales were $444 million, up 14%. Lucentis sales were down 24% to $301 million.
 
Earnings growth was driven by higher operating income and non- recurring favorable tax impacts.  During the year, Novartis completed its transformation into a “pure-play” innovative medicines business focused on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience and oncology.
 
Discontinued operations include the Sandoz generic pharmaceuticals and biosimilars division, certain corporate activities attributable to Sandoz prior to the spin-off up to the distribution date of October 3, 2023, and certain other expenses related to the spin-off.